MINDBIO THERAPEUTICS BEGINS DOSING MB22001 IN PHASE 2 CLINICAL TRIAL IN WORLD FIRST TAKE-HOME MICRODOSING STUDY IN PATIENTS WITH DEPRESSION World-first take-home approvals...
MINDBIO THERAPEUTICS BREAKTHROUGH DISCOVERY IN MICRODOSING CLINICAL TRIAL REVEALS SIGNIFICANT POSITIVE EFFECTS ON QUALITY OF SLEEPNew Discovery: MindBio's LSD-Microdosing Treatment Improves...
MINDBIO THERAPEUTICS CEO DEMONSTRATES HOW 1 MILLION MICRODOSES OF LSD CAN POTENTIALLY BE USED TO TREAT DEPRESSION 1 Million Microdoses used to create proprietary microdosing...
ETHICS APPROVAL FOR LANDMARK WORLD FIRST PHASE 2 CLINICAL TRIAL OF TAKE-HOME LSD-MICRODOSING FOR MAJOR DEPRESSIVE DISORDEREthics approval received for take-home LSD-Microdosing clinical...
PHASE 2 CLINICAL TRIAL HAS RECEIVED ETHICS APPROVAL FOR WORLD FIRST TAKE-HOME LSD-MICRODOSING TRIALS IN CANCER PATIENTS EXPERIENCING EMOTIONAL DISTRESSEthics approval granted The clinical trial...
MindBio Therapeutics Corp (CSE: MBIO) Reveals Scientific Paper in World-First Take-Home, LSD-Microdosing Clinical Trial in 80 Healthy Participants MindBio clinical trial...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.005 | 16.6666666667 | 0.03 | 0.035 | 0.03 | 156052 | 0.03279228 | CS |
4 | 0.01 | 40 | 0.025 | 0.035 | 0.025 | 52010 | 0.0317023 | CS |
12 | 0.005 | 16.6666666667 | 0.03 | 0.04 | 0.025 | 34025 | 0.03098647 | CS |
26 | -0.02 | -36.3636363636 | 0.055 | 0.07 | 0.025 | 41426 | 0.0384308 | CS |
52 | 0.01 | 40 | 0.025 | 0.085 | 0.015 | 44860 | 0.04298633 | CS |
156 | -0.525 | -93.75 | 0.56 | 0.56 | 0.015 | 61171 | 0.06345987 | CS |
260 | -0.525 | -93.75 | 0.56 | 0.56 | 0.015 | 61171 | 0.06345987 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約